Concepedia

Jin Xia

JX

Statistics

Publications

4

Citations

168

H-Index

4

Active since

2013

Affiliations

Anyang Tumor Hospital(Current)

First Affiliated Hospital of Zhengzhou University

First Affiliated Hospital of Henan University of Science and Technology

Xinyang Central Hospital

Jiangsu Hengrui Medicine (China)

Jin Xia is an author at Anyang Tumor Hospital specializing in oncology, pathology, and medicine.

Top concepts

MedicineOncologyPathologyCancer TherapyRadiation OncologyTumor BiologyCancer ResearchSurgical OncologyMolecular OncologyImmune Surveillance

Publications per year

2013–2024

4

Publications

4

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Xiangrui Meng, Tao Wu, Yonggui Hong et al. · The Lancet. Gastroenterology & hepatology · 2022 · 82 citations

Second-line Treatment, Oncology, Esophageal Cancer +6

miR-145 Inhibits Proliferation and Invasion of Esophageal Squamous Cell Carcinoma in Part by Targeting c-Myc

Feng Wang, Jin Xia, Nengchao Wang et al. · Onkologie · 2013 · 55 citations

Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM‑independent enrichment and immunostaining‑fluorescence in�situ hybridization

Yaowen Zhang, Jian Li, Lu Wang et al. · Molecular Medicine Reports · 2019 · 18 citations · Full text

Surgical Oncology, Esophageal Cancer, Pathology +18

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study

Xiangrui Meng, Junsheng Wang, Jin Xia et al. · European Journal of Cancer · 2024 · 13 citations

1–4 of 4